VIR

Vir Biotechnology, Inc. (VIR) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Vir Biotechnology is a clinical-stage biopharmaceutical company focused on infectious diseases (specifically Chronic Hepatitis Delta and HIV) and oncology (dual-masked T-cell engagers). The company operates as a single reportable segment and is currently incurring net losses while advancing its clinical pipeline.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenue for the six months ended June 30, 2025, dropped significantly to $4.2 million from $59.5 million in the prior year. This decrease was primarily driven by the expiration of GSK collaboration rights in March 2024 (which generated $51.7 million in deferred revenue recognition in Q1 2024) and lower grant revenue from the Gates Foundation and BARDA.
• Net Loss Increase: The net loss for the six months ended June 30, 2025, increased to $231.9 million from $203.7 million in the prior year. This was largely due to a $30.0 million expense related to the Restated Alnylam Agreement and milestone payments for the ECLIPSE registrational program, partially offset by cost-saving initiatives.
• Operating Expense Reduction: Total operating expenses decreased by $36.0 million year-over-year for the six-month period, driven by lower personnel expenses (headcount reductions) and the completion of restructuring initiatives.
• Collaboration Revenue: Collaboration revenue turned negative in Q2 2025 ($(0.5) million) compared to positive revenue in prior periods, reflecting adjustments to profit-sharing amounts with GSK.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing cash, cash equivalents, and investments ($892.1 million) are sufficient to fund operations for at least the next 12 months. No shares have been sold under the $300 million At-The-Market (ATM) sales agreement with Cowen as of June 30, 2025.
• Clinical Progress:
  • Hepatitis Delta: The ECLIPSE registrational program is fully underway with all three trials initiated.
  • Oncology: First patient dosed in July 2025 for VIR-5525 (EGFR-targeted TCE). Phase 1 studies for VIR-5818 (HER2) and VIR-5500 (PSMA) are advancing.
• Strategic Agreements:
  • Sanofi: Closed a license agreement for the PRO-XTEN masking platform and three TCEs in September 2024, involving a $100 million upfront payment and a $75 million milestone escrow.
  • Alnylam: Paid $30.0 million in Q2 2025 to restructure the agreement for elebsiran, moving to a milestone/royalty model rather than profit-sharing.
• Risks: The company faces significant risks related to the uncertainty of clinical trial outcomes, the need for substantial additional capital, and the revocation of the EUA for sotrovimab (COVID-19), from which no meaningful future revenue is expected.

Investor Verification Checklist

• Verify the timeline and enrollment status of the ECLIPSE registrational program for Chronic Hepatitis Delta, as this is a primary value driver.
• Confirm the cash runway given the high burn rate (~$232M loss in 6 months) and the potential need for future capital raises.
• Monitor the milestone payment obligations under the Sanofi and Alnylam agreements, specifically the $75 million escrow for VIR-5525 first-in-human dosing (achieved July 2025).
• Review the impact of the Restated Alnylam Agreement on future royalty and milestone liabilities versus the previous profit-sharing model.
• Assess the collaboration revenue volatility with GSK, noting the shift from profit-sharing to potential negative adjustments.